Literature DB >> 10472343

Polyamines in human breast cancer and its relations to classical prognostic features: clinical implications.

J Leveque1, J Y Bansard, E Watier, V Catros-Quemener, R Havouis, J P Moulinoux, J Y Grall, N Seiler.   

Abstract

Experimental evidence suggest an important role of polyamines in breast cancer development. Polyamines have been determined in tissue and erythrocyte samples from 100 patients with primary invasive breast cancer and 30 patients with fibroadenomas. Statistical analysis was performed in order to determine the prognostic value of the polyamine patterns of tumor tissues and erythrocytes in comparison with clinical and histological prognostic factors. In malignant tissues, polyamine levels were significantly higher than in benign tissues. They correlated with markers of tumor aggressivity (axillary node involvement and especially with markers of high mitotic rate as Ki-67 staining, histological grade). No correlation was found between estrogen and progesterone status, tumor size and polyamine concentrations. Erythrocyte polyamines levels were identical between cancer patients and controls. The knowledge of the polyamine pattern in breast cancer could become useful in clinical practice particularly if polyamine metabolism is targeted as a therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472343

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  Polyamine Immunometabolism: Central Regulators of Inflammation, Cancer and Autoimmunity.

Authors:  Tzu-Yi Chia; Andrew Zolp; Jason Miska
Journal:  Cells       Date:  2022-03-05       Impact factor: 6.600

2.  Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.

Authors:  Gianmaria Miolo; Elena Muraro; Donatella Caruso; Diana Crivellari; Anthony Ash; Simona Scalone; Davide Lombardi; Flavio Rizzolio; Antonio Giordano; Giuseppe Corona
Journal:  Oncotarget       Date:  2016-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.